Lupin Limited (LUPIN) — Announcement | 10 August 2026(2 announcements)

Lupin Limited announced its participation in several upcoming investor conferences, including Equirus Annual India Conference on August 13, 2026, Emkay Confluence 2026 on August 14, Motilal Oswal Global Investor Conference on August 18, Antique Healthcare Investor Conference on August 25, and Elara India Dialogue 2026 on September 1. These in-person group meetings will allow analysts and institutional investors to engage with the company, with presentations aligned to existing public materials. The filing emphasizes regulatory compliance under SEBI Listing Regulations and notes that event dates may change. This schedule provides investors with multiple opportunities to assess Lupin's strategy and performance amid ongoing market dynamics.

Lupin Limited announced that the U.S. FDA approved its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet, indicated for treating hyperkalemia in adults. The product is bioequivalent to AstraZeneca's Lokelma® and targets a U.S. market estimated at $568 million in annual sales. This regulatory milestone expands Lupin's presence in the high-value U.S. specialty generics segment and positions it to capture growth in a therapeutic area with limited competition. The approval underscores the company's capability to bring complex generic drugs to market and enhances shareholder value through potential revenue diversification and margin accretion from higher-margin specialty products.